Nicki Minaj made a surprise appearance at Turning Point USA’s AmericaFest on Sunday in Phoenix alongside Erika Kirk, the widow of TPUSA founder Charlie Kirk and the organization’s CEO. The pair ...

Notre Dame values its independence more than it cares about college football’s postseason. Potential for CFP bracket expansion is another reason for Notre Dame to not join a conference. Irish ...

TIOBE Index for December 2025: R Joins the Top 10 as SQL Climbs Your email has been sent December’s TIOBE Index closes the year with a steady upper tier and a few late surprises in the lower ranks.

Abstract: In this paper, recursive least-squares linear estimation algorithms are proposed for stochastic systems influenced by uniform quantization, random access protocol (RAP) and deception attacks ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Michelle Grattan does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

WASHINGTON—Syria has joined the U.S.-led mission to defeat Islamic State, U.S. officials said, after President Trump and Syrian President Ahmed al-Sharaa met at the White House on Monday. The move ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...